Briefings in Bioinformatics · 2024 · 17 citations · 25 references
PharmacyBiochemistryMedicinal ChemistryComputational BiologyDrug DiscoveryMachine LearningComputational Drug DiscoveryDrug Knowledge RepresentationPeptide Drug DiscoveryPeptide IdentificationDeep Feature LearningEnzymatic Cleavage MechanismsHalf-life PredictionPeptide Drug DevelopmentPost-translationally Modified PeptidesPredictive Model PerformancePredictive PerformanceTransfer Learning For Molecular Property Prediction
Peptide drugs are becoming star drug agents with high efficiency and selectivity which open up new therapeutic avenues for various diseases. However, the sensitivity to hydrolase and the relatively short half-life have severely hindered their development. In this study, a new generation artificial intelligence-based system for accurate prediction of peptide half-life was proposed, which realized the half-life prediction of both natural and modified peptides and successfully bridged the evaluation possibility between two important species (human, mouse) and two organs (blood, intestine). To achieve this, enzymatic cleavage descriptors were integrated with traditional peptide descriptors to construct a better representation. Then, robust models with accurate performance were established by comparing traditional machine learning and transfer learning, systematically. Results indicated that enzymatic cleavage features could certainly enhance model performance. The deep learning model integrating transfer learning significantly improved predictive accuracy, achieving remarkable R2 values: 0.84 for natural peptides and 0.90 for modified peptides in human blood, 0.984 for natural peptides and 0.93 for modified peptides in mouse blood, and 0.94 for modified peptides in mouse intestine on the test set, respectively. These models not only successfully composed the above-mentioned system but also improved by approximately 15% in terms of correlation compared to related works. This study is expected to provide powerful solutions for peptide half-life evaluation and boost peptide drug development.
25
The ProteomeXchange consortium at 10 years: 2023 update
Eric W. Deutsch, Nuno Bandeira, Yasset Pérez‐Riverol et al. · Nucleic Acids Research · 2022 · 865 citations · Full text
THPdb: Database of FDA-approved peptide and protein therapeutics
Salman Sadullah Usmani, Gursimran Bedi, Jesse S. Samuel et al. · PLoS ONE · 2017 · 488 citations · Full text